The use of antibodies in the prophylaxis and treatment of infections

Emerging Microbes and Infections

Volumn 1, Issue , 2012, Pages

  Lachmann, Peter J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibodies; Flu; Infection

Indexed keywords

ANTIBODY; CD3 ANTIGEN; FC RECEPTOR; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VACCINE;

ANTIGENICITY; BACTERIAL INFECTION; DENGUE VIRUS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFANTILE GASTROENTERITIS; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; VIRUS STRAIN;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 84878380007     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2012.2     Document Type: Review

References (23)

1. Silverstein AM. Cellular versus humoral immunity: determinants and consequences of an epic nineteenth century battle. In: Silverstein AM, editors. A History of Immunology. 1st ed. New York: Academic Press Inc.; 1989. pp38-58.
2. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599-609. (Pubitemid 46780940)
3. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447-456.
4. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
5. Houdebine LM. Transgenic animal bioreactors. Transgenic Res 2000; 9: 305-320.
6. Lillico SG, Sherman A, McGrew MJ et al. Oviduct-specific expression of two therapeutic proteins in transgenic hens. Proc Natl Acad Sci USA 2007; 104: 1771-1776. (Pubitemid 46239854)
7. Hamers-Casterman C, Atarhouch T, Muyldermans S et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-448. (Pubitemid 23179389)
8. van der Linder RH, Frenken LG, de Geus B et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999; 1431: 37-46. (Pubitemid 29182720)
9. Kaplan MH. Immunologic relationship of group A streptococcal strains and human heart tissue. Possible significance for the pathogenesis of rheumatic fever. Am Heart J 1963; 65: 426-427.
10. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Amer J Epidemiol 1979; 110: 105-123. (Pubitemid 10209694)
11. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré Syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169: 382-388.
12. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60: 421-467. (Pubitemid 137639381)
13. Dejnirattisai W, Jumnainsong A, Onsirisakul N et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328: 745-748.
14. Balsitis SJ, Williams KL, Lachica R et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6: e1000790.
15. Davis D, Chaudhri B, Stephens DM, Carne CA, Willers C, Lachmann PJ. The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. J Gen Virol 1990; 71: 1975-1983. (Pubitemid 20296440)
16. Taussig MJ, Lachmann PJ. Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. Immunol 1972; 22: 185-197.
17. 1 memory B cells. PLoS ONE 2008; 3: e3942.
18. Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-273.
19. Friesen RH, Koudstaal W, Koldijk MH et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE 2010; 5: e9106.
20. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028. (Pubitemid 44343545)
21. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
22. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010; 40: 190-203.
23. Renegar K, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173: 1978-1986. (Pubitemid 38971634)